Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a milk protein cream soothe Kids' eczema?

NCT ID NCT07259343

Recruiting now Symptom relief Sponsor: Universidad Autónoma de Aguascalientes Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tests whether a cream made with glycomacropeptide, a milk protein, can reduce eczema symptoms in children aged 2 to 12 with mild atopic dermatitis. Twenty children will apply either the glycomacropeptide cream or a standard moisturizer twice daily for four weeks. Researchers will track changes in skin severity, itching, sleep quality, and skin bacteria levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
glycomacropeptide cream
What this could lead to
If it works, this could point toward a new topical option to reduce itching and skin severity in children with mild eczema.
What could go wrong
This is a very small pilot study with only 20 children, so results may not apply broadly. The cream may not outperform a standard emollient.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema Eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS (AD)

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Universidad Autónoma de Aguascalientes

    RECRUITING

    Aguascalientes, Aguascalientes, 20100, Mexico

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.